结论：益气通络丹的疗效机制与抑制脂质过氧化、保护内皮依赖性松弛因子和调节纤溶活性有关。
Conclusion: the protective mechanisms of YQTLP were related to inhibit lipid peroxidation, protect endothelium-derived relaxing factor and adjust the fibrinolytic activities.
用酶联免疫吸附法检测血浆血管性假性血友病因子、凝血酶调节蛋白、纤溶酶原激活物抑制物1水平。
The von Willebrand's disease factors in plasm, adjusted protein of thrombase and inhibitor 1 of activator of plasminogen were detected with enzyme-linked immunosorbent assay.
为探讨纤溶酶原激活物抑制因子1（PAI 1）在肾损伤后纤维化中的作用和意义，揭示其发病的分子病理机制。
ObjectiveTo study the role and significance of plasminogen activator inhibitor-1(PAI-1) in renal fibrosis(RF) after damage and elucidate the molecular pathogenetic mechanisms of RF.
目的研究前炎症细胞因子对人胸膜间皮细胞（HPMC）释放纤溶酶原激活物抑制剂（PAI1）的诱导效应。
Objective To investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor 1(PAI 1) by human pleural mesothelial cells(HPMC).
血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。
Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.
血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。
Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.
应用推荐